Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Aliqopa
|
| gptkbp:chemicalFormula |
C22H24ClN5O3S
|
| gptkbp:clinicalTrials |
Phase II
NCT02477696 NCT02003678 NCT02379051 NCT02905925 NCT02909833 overall response rate of 59% in clinical trials |
| gptkbp:contraindication |
anemia
hypertension rash active infections pneumonitis severe hepatic impairment increased liver enzymes |
| gptkbp:developedBy |
gptkb:Bayer_AG
|
| gptkbp:dosageForm |
solution for infusion
|
| gptkbp:drugInterdiction |
CYP3A4 inhibitors
CYP3A4 inducers half-life of approximately 88 hours |
| gptkbp:firstAppearance |
September 2017
|
| gptkbp:formulation |
lyophilized powder for reconstitution
|
| gptkbp:hasPopulation |
adults
|
| https://www.w3.org/2000/01/rdf-schema#label |
Copanlisib
|
| gptkbp:impact |
up to 12 cycles
|
| gptkbp:isATypeOf |
1207450-98-3
|
| gptkbp:mandates |
relapsed follicular lymphoma
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:nutritionalValue |
primarily hepatic
|
| gptkbp:renovated |
dilute with sterile water for injection
|
| gptkbp:researchFocus |
cancer therapy
lymphoma treatment PI3K_pathway_inhibitors |
| gptkbp:route |
intravenous
|
| gptkbp:sideEffect |
fatigue
nausea diarrhea thrombocytopenia hyperglycemia |
| gptkbp:storage |
store at 2°C to 8°C
|
| gptkbp:targets |
PI3K_pathway
|
| gptkbp:triggerType |
PI3K_inhibitor
|
| gptkbp:usedFor |
treatment of follicular lymphoma
|
| gptkbp:waterManagement |
urine and feces
|